Hair thinning on hormone replacement therapy is common in the first two to three months of estrogen, testosterone, or thyroid adjustment, and in most cases it is a temporary shedding pattern called telogen effluvium, not permanent loss. This guide walks through what causes it, how to tell if your protocol needs a change, and the specific steps that stop the shedding without abandoning therapy that is otherwise working.

TL;DR

  • Hair thinning on hormone replacement therapy is usually telogen effluvium, not permanent loss, and it resolves in 3 to 6 months.
  • Ferritin under 30 ng/mL and an untreated thyroid shift make shedding worse before any hormone dose is the real problem.
  • Testosterone or DHEA can trigger androgenic thinning in women; ask your clinician about dose and route before stopping therapy.
  • Track shedding weekly for 90 days instead of daily counting, which overestimates the problem and causes premature dose changes.
  • Verdict: don't quit hormone replacement therapy over hair alone. Get labs first, then adjust.

Why this matters

Hair follicles run on a cycle: growth, rest, shed. A hormone shift, whether it's starting estrogen, adjusting testosterone, or correcting a thyroid dose, can push a larger-than-usual batch of follicles into the resting phase at once. You don't see the shed for 8 to 12 weeks because that's how long the resting phase lasts before the hair actually falls out.

This is the piece most patients never get told: the shedding you notice in month three is often tied to a hormone change from month one. Panicking and stopping hormone replacement therapy mid-cycle usually just resets the clock and triggers a second round of shedding. Weight, hormones, thyroid, and inflammation are one interconnected system, and hair is often the visible signal that one part of that system is under-supported, not that the hormone therapy itself is wrong.

GoodLife Health's Cardiometabolic Optimization Membership treats hair thinning as a labs-first problem: ferritin, thyroid panel, and sex hormone levels get checked before any dose gets changed, because guessing at a fix without data usually makes the shedding last longer.

What you'll need

  • A ferritin and full iron panel drawn within the last 90 days
  • A complete thyroid panel (TSH, free T3, free T4) — not TSH alone
  • Your baseline sex hormone levels from before starting therapy, if available
  • A photo or count baseline: 20-30 count during a normal shower is average; anything sustained above 100-150 strands over several weeks warrants a look
  • 90 days of patience — most protocol adjustments need a full quarter to show in hair, not weeks
  • A clinician who will actually review labs against your hormone dose, not just refill a prescription

The steps

1. Confirm it's shedding, not breakage

Telogen effluvium sheds hair with a small white bulb at the root; breakage snaps mid-shaft with no bulb. This distinction changes the entire plan. Breakage points to heat styling, chemical treatments, or protein deficiency, not your hormone dose. Common mistake: blaming hormone replacement therapy for damage that started with a new flat iron routine.

2. Pull ferritin and a full iron panel

Ferritin below 30 ng/mL is a well-documented driver of hair shedding independent of hormones, and levels under 70 ng/mL slow regrowth even when the rest of the panel looks normal. Low ferritin combined with a new hormone dose is the most common reason patients see thinning that lingers past the 3 to 6 month window. Common mistake: checking only hemoglobin, which can be normal while ferritin is depleted.

3. Get a complete thyroid panel, not TSH alone

Estrogen changes thyroid-binding globulin, which can shift free thyroid hormone levels even when TSH sits in range. A subclinical thyroid shift triggered by starting hormone therapy is one of the most overlooked causes of thinning in women starting estrogen in 2026. Ask specifically for free T3 and free T4 alongside TSH.

4. Review the specific hormone and route

Oral estrogen raises sex hormone binding globulin more than transdermal routes, which changes how much free testosterone circulates and can shift thinning patterns differently depending on the delivery method. Testosterone or DHEA supplementation in women can trigger androgenic thinning at the crown and temples through DHT conversion, distinct from the diffuse shedding of telogen effluvium. This is a dose-and-route conversation, not a stop-the-medication conversation.

5. Don't change two variables at once

If ferritin is low and your hormone dose was just adjusted, fix ferritin first and hold the hormone dose steady for one full cycle. Changing both at once makes it impossible to know which fix worked, and it resets the 90-day observation window you need to judge results. Common mistake: patients panic-adjust hormone dose and start three supplements in the same week, then can't tell what helped.

6. Support the follicle directly for 90 days

Minoxidil 5% applied to the scalp, adequate protein intake (roughly 0.7-1g per pound of target body weight), and correcting any vitamin D deficiency all shorten the resting phase. None of these replace fixing ferritin or thyroid, but they run in parallel while labs and hormone dosing catch up.

7. Recheck labs at 90 days, not 30

Hair growth is slow biology. A ferritin recheck or hormone dose reassessment at 30 days almost always looks unchanged and causes people to make a second unnecessary change. Wait the full quarter, then compare against your baseline photo and count.

Troubleshooting

Shedding started right after my first hormone dose increase. This is the classic telogen effluvium pattern and it typically peaks around 8-12 weeks post-change. Hold the dose, recheck ferritin, and reassess at 90 days rather than reversing the increase immediately.

My labs are all normal but I'm still shedding. Normal-range ferritin under 70 ng/mL is still low for hair specifically. Ask your clinician about supplementing toward the higher end of normal rather than accepting a technically-in-range result.

Thinning is at my crown and temples, not diffuse. This pattern points toward androgenic thinning, often tied to testosterone or DHEA dosing, and needs a different conversation than telogen effluvium. How to tell if your hormone therapy dose needs adjusting walks through what a dose review actually looks at.

I stopped hormone therapy and the shedding got worse. Abrupt discontinuation is its own hormone shock and can trigger a second telogen effluvium episode on top of the first. Reintroducing therapy under supervision, rather than restarting cold, is usually the better path.

It's been four months and nothing has changed. At this point the issue is likely not hormonal at all — check for autoimmune thyroid disease, an unaddressed nutrient deficiency, or a dermatologic cause that needs a specialist referral.

Tools and resources

What to do next

If shedding hasn't slowed by the 90-day mark despite a corrected ferritin and stable hormone dose, the next step is a full metabolic and hormone recheck rather than another supplement swap. Patients also managing weight loss alongside hormone therapy in 2026 often ask whether a GLP-1 medication complicates the picture — that's a separate mechanism worth understanding on its own, covered in how to find a weight loss doctor who prescribes GLP-1s.

FAQ

Does hormone replacement therapy always cause hair thinning?

No. Most patients on hormone replacement therapy in 2026 never notice thinning, and when it happens it's usually a temporary telogen effluvium episode tied to the hormone shift, not a permanent side effect of the therapy itself.

How long does hair thinning from hormone replacement therapy last?

Telogen effluvium from a hormone change typically resolves within 3 to 6 months once ferritin, thyroid, and dose are stable. Shedding that continues past 6 months needs a broader workup beyond hormones.

Is testosterone therapy worse for hair than estrogen therapy?

Testosterone and DHEA can trigger androgenic thinning through DHT conversion, which is a different pattern than the diffuse shedding seen with estrogen changes. The distinction matters because the fix differs: dose and route review versus ferritin and thyroid correction.

Should I stop hormone replacement therapy if my hair is thinning?

Stopping abruptly often causes a second shedding episode on top of the first and rarely fixes the underlying cause. Get ferritin and thyroid labs first, since low iron stores are the most common overlooked driver.

What ferritin level is needed to stop hair thinning?

Ferritin above 70 ng/mL supports better regrowth than a merely in-range result near 30-40 ng/mL. Many patients with technically normal ferritin still shed until levels are raised toward the higher end.

Can minoxidil be used alongside hormone replacement therapy?

Yes, topical minoxidil 5% is commonly used alongside hormone therapy to shorten the resting phase of the hair cycle while labs and dosing are corrected. It supports the fix but doesn't replace addressing ferritin or thyroid.

Why does hair loss show up months after starting hormone therapy?

Hair follicles pushed into the resting phase by a hormone shift don't shed for 8 to 12 weeks, so thinning noticed in month three is often tied to a change made in month one. This delay is why patients often blame the wrong cause.

Does thyroid function affect hair thinning during hormone therapy?

Yes. Estrogen changes thyroid-binding globulin, which can shift free thyroid hormone levels even when TSH looks normal, and subclinical thyroid changes are a frequently missed cause of thinning during hormone adjustments.

One last thing

The detail most patients miss: a ferritin level that reads as "normal" on a standard lab report can still be too low for hair specifically, since the reference range for iron deficiency and the level your follicles actually need are two different thresholds. Ask for the number, not just the flag.

Related guides

References

  1. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. 2015. doi.org/10.1210/jc.2015-2236
  2. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018. doi.org/10.1210/jc.2018-00229